pharmaphorum

FEBRUARY 10, 2021

The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.

Chemotherapy 87

Chemotherapy Hospitals 87

Hospital Pharmacy Europe

AUGUST 30, 2022

Currently, it is recommended that stage I disease is treated with radiotherapy alone whereas concurrent chemotherapy (i.e., Despite the recommendation to combine IMRT and chemotherapy for patients with stage II NPC, there is a lack of supportive evidence for this approach. chemoradiotherapy) is advised for patients at stage II.

Chemotherapy 52

Chemotherapy Hospitals 52

STAT

FEBRUARY 14, 2024

The Federal Trade Commission is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to ongoing shortages of key medicines at hospitals and other facilities across the country. Three group purchasing organizations, or GPOs, buy drugs on behalf of most hospitals in the U.S.,

Nursing Homes 133

Nursing Homes Chemotherapy Hospitals 133

Pharmaceutical Technology

JANUARY 17, 2023

Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia. The post Hospital Universitario and Josep Carreras develop cell therapy for leukaemia appeared first on Pharmaceutical Technology.

Hospitals 110

Hospitals Chemotherapy Communication Immunization 110

STAT

SEPTEMBER 8, 2023

A large independent group of oncologists in Philadelphia is suing the area’s dominant hospital system, Jefferson Health, alleging the system is violating federal antitrust and kickback laws by creating a “concerted campaign to eliminate” the group’s “presence in the oncology marketplace.”

Hospitals 127

Hospitals Chemotherapy Insurance 127

STAT

SEPTEMBER 14, 2023

WASHINGTON — A nonprofit formed by hospitals to deal with drug shortages is considering a move into chemotherapies. Frustrated by drug shortages and the price spikes that typically ensue, executives from large hospital systems launched the nonprofit Civica Rx to deal with the problem in September 2018.

Hospitals 118

Hospitals Chemotherapy 118

Hospital Pharmacy Europe

JANUARY 24, 2024

The final draft guidance from NICE recommends talazoparib for the treatment of adults with BRCA 1 or 2 mutated HER2-negative locally advanced or metastatic breast cancer after prior chemotherapy. Evidence from a clinical trial showed that talazoparib increases how long people live without their cancer getting worse compared with chemotherapy.

Chemotherapy 101

Chemotherapy Hospitals 101

STAT

OCTOBER 20, 2023

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

Compounding 117

Compounding Chemotherapy Hospitals 117

STAT

APRIL 11, 2024

Diagnosed at age 3 with acute myeloid leukemia, an aggressive blood cancer, Logan happened to have a targetable mutation that occurs in a small minority of childhood AML cases, making it possible for him to receive a precision therapy drug that — with chemotherapy — got him to a point where he could receive a bone marrow transplant.

Chemotherapy 143

Chemotherapy Hospitals 143

Outsourcing Pharma

AUGUST 4, 2023

Scientists at a major US hospital have developed a âcancer-killing pillâ that appears to âannihilateâ solid tumors through targeted chemotherapy.

Chemotherapy 98

Chemotherapy Hospitals 98

STAT

JUNE 28, 2023

“Oftentimes we can cure kids of their disease, but we can’t do that without the drugs,” said Unguru, a pediatric hematologist oncologist at Children’s Hospital at Sinai in Baltimore and the Johns Hopkins School of Medicine. “It’s just so, so maddening.”

Chemotherapy 100

Chemotherapy Hospitals 100

STAT

OCTOBER 5, 2023

Based on questions posed to 29 of its 33 member hospitals, the National Comprehensive Cancer Network said Thursday that 86% of those cancer centers are experiencing a shortage of at least one type of generic chemotherapy drug, down from 90% in May.

Chemotherapy 116

Chemotherapy Hospitals 116

Hospital Pharmacy Europe

FEBRUARY 29, 2024

Adding an arginine-depleting agent to chemotherapy extends survival for patients with advanced non-epithelial pleural mesothelioma, a randomised controlled trial suggests. Pegargiminase-based chemotherapy was well tolerated, with no new safety signals, they added. mg/ m2) or placebo. mg/ m2) or placebo.

Chemotherapy 52

Chemotherapy Immunization Hospitals 52

Hospital Pharmacy Europe

NOVEMBER 9, 2023

A short course of induction chemotherapy (IC) ahead of standard treatment with chemotherapy and radiation reduces the rate of relapse and death in women with locally advanced cervical cancer, according to preliminary study findings presented at the European Society for Medical Oncology (ESMO) Congress 2023.

Chemotherapy 52

Chemotherapy Hospitals 52

STAT

AUGUST 11, 2023

Fifty-seven percent of hospital pharmacists said they are facing critical shortages of chemotherapy drugs in a new survey from the American Society of Health-System Pharmacists. Hospital pharmacists also reported significant shortages of steroids, hormonal drugs, and oral liquids such as amoxicillin and lidocaine.

Chemotherapy 89

Chemotherapy Hospitals 89

STAT

JULY 18, 2023

WASHINGTON — Medicare has a new proposal to pay hospitals more to stockpile essential drugs — an idea that comes as doctors report running low on critical chemotherapies and other drugs. But Medicare has its own new idea: paying hospitals to create a “buffer stock” of 86 medicines that HHS deems critical.

Hospitals 85

Hospitals Chemotherapy FDA 85

European Pharmaceutical Review

OCTOBER 1, 2022

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients.

Chemotherapy 89

Chemotherapy Immunization Hospitals 89

Hospital Pharmacy Europe

MARCH 14, 2024

The monoclonal antibody dostarlimab (brand name Jemperli) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in combination with platinum-based chemotherapy for eligible patients with endometrial cancer. It is not recommended for routine use in the NHS.

Chemotherapy 52

Chemotherapy Hospitals 52

Hospital Pharmacy Europe

DECEMBER 14, 2023

Dostarlimab (brand name Jemperli) has been granted marketing authorisation by the European Commission (EC) in combination with carboplatin-paclitaxel (chemotherapy) for certain types of endometrial cancer, its manufacturer GSK has announced.

Chemotherapy 52

Chemotherapy Adverse Reactions Hospitals 52

Hospital Pharmacy Europe

SEPTEMBER 1, 2023

However, where patients are receiving intravenous chemotherapy in combination with atezolizumab, they may remain on the transfusion. While the IMscin001 trial was conducted within the hospital setting, Roche has said that SC atezolizumab may also be suitable for out-of-hospital administration by a healthcare professional.

Chemotherapy 98

Chemotherapy Hospitals FDA 98

STAT

OCTOBER 5, 2022

She was rushed to the hospital, where doctors diagnosed the then 29-year-old with a brain tumor. After the brain tumor diagnosis in 2016, Gatton would undergo two brain surgeries, radiation treatment, chemotherapy, followed by an embryo transfer that failed.

Chemotherapy 106

Chemotherapy Hospitals 106

Hospital Pharmacy Europe

FEBRUARY 29, 2024

Statistically significant tislelizumab trials The RATIONALE 307 trial looked at first-line tislelizumab in combination with chemotherapy for patients with advanced squamous NSCLC. The most common grade ≥3 treatment emergent adverse events were associated with chemotherapy and included neutropenia and leukopenia.

Chemotherapy 52

Chemotherapy Hospitals 52

Hospital Pharmacy Europe

AUGUST 15, 2023

Participants with resectable stage II, IIIA, or IIIB NSCLC, were randomised 1:1 to receive neoadjuvant pembrolizumab (200 mg) or placebo once every three weeks, each of which was given with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every three weeks for up to 13 cycles.

Chemotherapy 96

Chemotherapy Immunization Hospitals 96

Hospital Pharmacy Europe

MARCH 22, 2023

Although programmed cell death protein 1 inhibitors such as pembrolizumab with chemotherapy significantly prolonged overall survival compared to placebo as a first-line treatment for advanced OSCC , much less is known about the value of programmed cell death ligand 1 (PD-L1) inhibitors for this cancer. Citation Li Y et al.

Chemotherapy 52

Chemotherapy Hospitals 52

STAT

SEPTEMBER 25, 2023

For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies used for many different cancers including ovarian, bladder, and lung cancer. We went to put in our chemotherapy order, and our supplier said, ‘We don’t have any.’ “It came without warning.

Chemotherapy 128

Chemotherapy Hospitals 128

European Pharmaceutical Review

APRIL 30, 2024

If approved, fruquintinib could provide a new oral, chemotherapy-free option as the first and only selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR) receptors approved in the EU for this disease, according to Takeda.

Generic Medicine 92

Generic Medicine Chemotherapy Hospitals FDA 92

pharmaphorum

NOVEMBER 28, 2021

The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. Jazz acquired rights to Sativex when it completed its $7.2

Chemotherapy 134

Chemotherapy FDA Hospitals 134

Pharmaceutical Technology

APRIL 12, 2023

The combined therapy includes toripalimab plus chemotherapy as peri-operative treatment and toripalimab monotherapy as consolidation therapy following adjuvant therapy. During the trial, patients with operable NSCLC were given toripalimab or a placebo along with platinum-based doublet chemotherapy as neoadjuvant and adjuvant therapy.

Chemotherapy 52

Chemotherapy Hospitals 52

Hospital Pharmacy Europe

AUGUST 17, 2023

Guidance on the provision of CAR T and cellular therapy services in hospital pharmacy has been published by the GoCART Coalition to harmonise implementation across Europe. 10 Once the CAR T-cells are manufactured, they are delivered to hospital pharmacies, making pharmacists central in ensuring appropriate governance and management.

Hospitals 98

Hospitals Documentation Chemotherapy Pharmaceutical Companies 98

Hospital Pharmacy Europe

AUGUST 23, 2023

Targeting CD40 with mitazalimab has the potential to augment responses to chemotherapy. Mitazalimab and OPTIMIZE-1 Mitazalimab is currently being evaluated in the phase 1b/2 OPTIMIZE-1 trial in combination with mFOLFIRINOX chemotherapy for adult patients with previously untreated metastatic PDAC. A median duration of response of 8.7

Chemotherapy 98

Chemotherapy Immunization Hospitals FDA 98

Hospital Pharmacy Europe

APRIL 12, 2024

Dr Sara Ghorashian, consultant in paediatric haematology at Great Ormond Street Hospital for Children NHS Foundation Trust, said: ‘During its time in the CDF, tisagenlecleucel has changed the way in which people with relapsed or refractory B-ALL have treatment. NHS use data found that the 24-month overall survival was 72% following treatment.

Hospitals 52

Hospitals Chemotherapy 52

pharmaphorum

JANUARY 3, 2023

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Chemotherapy 99

Chemotherapy Immunization Hospitals 99

European Pharmaceutical Review

JANUARY 30, 2024

The CHMP recommended Exblifep (cefepime/enmetazobactam) as a treatment for complicated urinary tract infections, including pyelonephritis, hospital-acquired pneumonia, including ventilator associated pneumonia, and for treating bacteraemia caused by the aforementioned infections.

Generic Medicine 97

Generic Medicine Chemotherapy Hospitals 97

Hospital Pharmacy Europe

SEPTEMBER 7, 2023

The use of adjunctive alectinib reduced disease recurrence in the early setting for people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) compared to platinum-based chemotherapy, its manufacturer Roche has announced. The OS data were immature at the time of the interim analysis.

Chemotherapy 52

Chemotherapy Labelling Hospitals 52

European Pharmaceutical Review

APRIL 3, 2023

In the Phase I New Approaches to Neuroblastoma Therapy (NANT) trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in patients with relapsed/refractory anaplastic lymphoma kinase (ALK)-driven neuroblastoma. However, it held promise when given in combination with chemotherapy. “As

Chemotherapy 79

Chemotherapy Hospitals FDA 79

Hospital Pharmacy Europe

SEPTEMBER 11, 2023

They identified a total of 28 genes in 12 strains of chemoresistant cell lines each against cisplatin, 5-fluorouracil, paclitaxel and docetaxel chemotherapies. Unfortunately, there are lots of people out there who do not respond to chemotherapy or radiation. In Europe, head and neck cancers affect around 22 people per 100,000.

Chemotherapy 59

Chemotherapy Compounding Hospitals 59

European Pharmaceutical Review

NOVEMBER 6, 2023

In addition to being indicated in those with progressive disease, Mirati Therapeutics shared that the treatment is also authorised for patients with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.

Chemotherapy 90

Chemotherapy Hospitals 90